EDITORIAL SECTION

Articles

Generative AI in Pharma: Scaling Productivity without Compromising

Most enterprise technologies enter a pharmaceutical company through a single door A manufacturing execution system arrives at a site A clinical data platform arrives in development Governance follows the deployment because there is a deployment to govern Generative AI did not behave this way It reached medical writers regulatory managers safety officers market access teams and commercial staff sim...

B2B Pharma Editorial Opportunities: Boosting Brand Visibility in Industry Magazines

The teams which previously counted greatly on banner advertisements email newsletters and sponsorship of various events are beginning to reevaluate the source of true influence Since such channels have a role to play they seldom earn credibility alone In contrast a wellplaced article in a respected industry publication can do something most campaigns struggle to achieveit makes people take you ser...

Pharma Event Marketing in Europe: Virtual & Hybrid Strategies to Drive High-Quality Leads

It is likely that you have attended some pharma event recently say in Frankfurt or Basel or even online and have noticed one thing Nothing wants lack of activity Booths are busy Webinars get registrations Virtual platforms show decent attendance numbers But when the dust settles a familiar problem shows up again

Pharmaceutical Business Strategy: Transformation, Regulation, Outsourcing and Growth

The pharmaceutical industry is standing at an unusual crossroads Patent cliffs are steeper regulators are tougher patients expect more transparency and payers are pushing back harder on price In this environment a strong Pharma Business Strategy is no longer a slide deck exercise for the boardroom its the difference between a company that scales globally and one that quietly fades into irrelevanc...

Intelligent Collaborations: Navigating the Current Biopharma M&A Rebound

Biopharma MA didnt collapse in and it recalibrated Deal volumes softened valuations compressed and acquirers grew cautious as macroeconomic headwinds elevated interest rates and regulatory scrutiny made largescale consolidation feel riskier than it once had But the underlying drivers never went away They accumulated

Brain Delivery of Biologics with Trojan Horse Shuttles: Remembering Paracelsus

Paracelsus in the th century established the principle of toxicology that the dose of a medicinal defines the difference between a remedy and a toxic effect

Techno Trends

Juniper Biosciences Secures FDA Breakthrough Designation

The US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to Juniper Biosciences JBS Ffluoromisonidazole or FMISO for identifying tumour hypoxia in patients with HPVpositive oropharyngeal carcinoma OPC

Projects

Onyx Scientific to Invest Over US$2 Million (£1.5 Million) in Sunderland GMP Facility Expansion

Onyx Scientific is investing more than US Million Million to expand its Good Manufacturing Practice GMP facilities at its Sunderland UK site The investment will increase capacity for commercial

Research Insights

One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases

Idarubicine is a mainstay of the treatment strategy for hematological cancer The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys